Intrarosa

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Prasterone

Available from:

Endoceutics S.A.

ATC code:

G03XX01

INN (International Name):

prasterone

Therapeutic group:

Oħrajn tal-ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema

Therapeutic area:

Postmenopause

Therapeutic indications:

Intrarosa hija indikata għat-trattament ta 'atrofija vulvari u vaġinali fin-nisa wara l-menopawża li għandhom sintomi moderati sa severi.

Product summary:

Revision: 6

Authorization status:

Awtorizzat

Authorization date:

2018-01-08

Patient Information leaflet

                                23
B.
FULJETT TA’ TAGĦRIF
24
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
INTRAROSA 6.5 MG PESSARJU
prasterone
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Intrarosa u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tuża Intrarosa
3.
Kif għandek tuża Intrarosa
4.
Effetti sekondarji possibbli
5.
Kif taħżen Intrarosa
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU INTRAROSA U GĦALXIEX JINTUŻA
Intrarosa fih is-sustanza attiva prasterone.
Għalxiex jintuża Intrarosa
Intrarosa jintuża biex jikkura nisa ta’ wara l-menopawża li
jkollhom sintomi moderati sa severi ta’
atrofija vulvari jew vaġinali. Dan jintuża biex itaffi s-sintomi
ta’ wara l-menopawża fil-vaġina bħal
nixfa jew irritazzjoni. Din tiġi kkawżata minn tnaqqis fil-livelli
ta’ estroġenu f’ġismek. Dan iseħħ
b’mod naturali wara l-menopawża.
Kif jaħdem Intrarosa
Prasterone jfejjaq is-sintomi u s-sinjali ta’ atrofija vulvari u
vaġinali billi jissostitwixxi l-estroġeni li
normalment jiġu prodotti qabel il-menopawża mill-ovarji tan-nisa.
Dan jiddaħħal fil-vaġina tiegħek,
biex b’hekk l-ormon jiġi rilaxxat fejn ikun meħtieġ. Dan jista’
jtaffi l-iskumdità fil-vaġina.
2.
X’GĦANDEK TKUN TAF QABEL MA TUŻA INTRAROSA
L-użu ta’terapija ta’ sostituzzjoni tal-ormoni (HRT) iġib
miegħu riskji li jeħtieġ li jiġu kkunsidrati
meta tiddeċiedi jekk tibdiex toħodha, jew jekk għandekx tibqa
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Intrarosa 6.5 mg pessarju
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull pessarju fih 6.5 mg ta’ prasterone.
Għal-lista sħiħa ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pessarju
Pessarju f’forma ta’ balla abjad għal jagħti fl-abjad, twil
madwar 28 mm u b’dijametru ta’ 9 mm fit-
tarf oħxon tiegħu.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Intrarosa huwa indikat għat-trattament ta’ atrofija vulvari u
vaġinali f’nisa ta’ wara l-menopawża li
jkollhom sintomi moderati sa severi.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża rakkomandata hija ta’ 6.5 mg prasterone (pessarju wieħed)
mogħtija darba kuljum, qabel il-
ħin tal-irqad.
Għat-trattament ta’ sintomi ta’ wara l-menopawża, Intrarosa
għandu jinbeda biss għal sintomi li
jaffettwaw il-kwalità tal-ħajja b’mod ħażin. Fil-każijiet
kollha, għandha titwettaq valutazzjoni mill-
ġdid bir-reqqa tar-riskji u tal-benefiċċji tal-inqas kull 6 xhur u
Intrarosa għandu jitkompla biss sakemm
il-benefiċċju jkun akbar mir-riskju.
Jekk pazjent jinsa jieħu doża, din għandha tittieħed malli
l-pazjent jiftakar. Madankollu, jekk id-doża
li jmiss tkun f’inqas minn 8 sigħat, il-pazjent għandu jaqbeż
il-pessarju li jkun qabeż. M’għandhomx
jintużaw żewġ pessarji biex ipattu għal kull pessarju li l-pazjent
ikun nesa jieħu.
_ _
_Popolazzjonijiet speċjali _
_ _
_Anzjani _
Mhu meħtieġ l-ebda aġġustament fid-doża fin-nisa anzjani.
_ _
_Pazjenti b’indeboliment tal-kliewi u/jew tal-fwied _
Peress li Intrarosa jaġixxi lokalment fil-vaġina, mhu meħtieġ
l-ebda aġġustament fid-dożaġġ f’nisa ta’
wara l-menopawża li jkollhom indeboliment tal-kliewi jew tal-fwied
jew kwalunkwe anomalija jew
marda sistemika oħra.
_ _
_Popolazzjoni pedjatrika _
M’hemm l-ebda użu rilevanti ta’ Intrarosa fi tfal bniet ta’
kwalunkwe grupp ta’ età għall-indikazzjoni
ta’ atrofija vulv
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-01-2024
Public Assessment Report Public Assessment Report Bulgarian 14-02-2018
Patient Information leaflet Patient Information leaflet Spanish 15-01-2024
Public Assessment Report Public Assessment Report Spanish 14-02-2018
Patient Information leaflet Patient Information leaflet Czech 15-01-2024
Public Assessment Report Public Assessment Report Czech 14-02-2018
Patient Information leaflet Patient Information leaflet Danish 15-01-2024
Public Assessment Report Public Assessment Report Danish 14-02-2018
Patient Information leaflet Patient Information leaflet German 15-01-2024
Public Assessment Report Public Assessment Report German 14-02-2018
Patient Information leaflet Patient Information leaflet Estonian 15-01-2024
Public Assessment Report Public Assessment Report Estonian 14-02-2018
Patient Information leaflet Patient Information leaflet Greek 15-01-2024
Public Assessment Report Public Assessment Report Greek 14-02-2018
Patient Information leaflet Patient Information leaflet English 15-01-2024
Public Assessment Report Public Assessment Report English 14-02-2018
Patient Information leaflet Patient Information leaflet French 15-01-2024
Public Assessment Report Public Assessment Report French 14-02-2018
Patient Information leaflet Patient Information leaflet Italian 15-01-2024
Public Assessment Report Public Assessment Report Italian 14-02-2018
Patient Information leaflet Patient Information leaflet Latvian 15-01-2024
Public Assessment Report Public Assessment Report Latvian 14-02-2018
Patient Information leaflet Patient Information leaflet Lithuanian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-01-2024
Public Assessment Report Public Assessment Report Lithuanian 14-02-2018
Patient Information leaflet Patient Information leaflet Hungarian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 15-01-2024
Public Assessment Report Public Assessment Report Hungarian 14-02-2018
Patient Information leaflet Patient Information leaflet Dutch 15-01-2024
Public Assessment Report Public Assessment Report Dutch 14-02-2018
Patient Information leaflet Patient Information leaflet Polish 15-01-2024
Public Assessment Report Public Assessment Report Polish 14-02-2018
Patient Information leaflet Patient Information leaflet Portuguese 15-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 15-01-2024
Public Assessment Report Public Assessment Report Portuguese 14-02-2018
Patient Information leaflet Patient Information leaflet Romanian 15-01-2024
Public Assessment Report Public Assessment Report Romanian 14-02-2018
Patient Information leaflet Patient Information leaflet Slovak 15-01-2024
Public Assessment Report Public Assessment Report Slovak 14-02-2018
Patient Information leaflet Patient Information leaflet Slovenian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 15-01-2024
Public Assessment Report Public Assessment Report Slovenian 14-02-2018
Patient Information leaflet Patient Information leaflet Finnish 15-01-2024
Public Assessment Report Public Assessment Report Finnish 14-02-2018
Patient Information leaflet Patient Information leaflet Swedish 15-01-2024
Public Assessment Report Public Assessment Report Swedish 14-02-2018
Patient Information leaflet Patient Information leaflet Norwegian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 15-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 15-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 15-01-2024
Patient Information leaflet Patient Information leaflet Croatian 15-01-2024
Public Assessment Report Public Assessment Report Croatian 14-02-2018

Search alerts related to this product

View documents history